IRLAB Therapeutics AB Class A's total assets for Q4 2024 were kr136.21M, a decrease of -15.02% from the previous quarter. SE:IRLAB.A total liabilities were kr103.58M for the fiscal quarter, a -15.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.